Why is GeneDx facing a securities class action lawsuit?

Investors allege GeneDx made misleading statements about reimbursement trends, profit margins, and the importance of certain business assets.

What are investors claiming about Fabric Genomics in the GeneDx lawsuit?

The complaint alleges GeneDx may have overstated the significance and impact of Fabric Genomics on its business performance.

Why is Fabric Genomics important to GeneDx investors?

Investors evaluate acquisitions and strategic assets based on their ability to support growth, revenue, and profitability.

What are reimbursement rates and why do they matter to GeneDx?

Reimbursement rates determine how much healthcare payors compensate for testing services and can significantly affect revenue.

What are investors alleging about GeneDx’s reimbursement rates?

Plaintiffs claim the company overstated the durability and sustainability of its reimbursement levels.

How could reimbursement changes affect GeneDx’s financial results?

Lower reimbursement rates can reduce revenue, pressure margins, and impact future earnings expectations.

What are investors alleging about GeneDx’s profit margins?

The lawsuit claims the company failed to disclose factors that could lead to declining gross margins.

Why are gross margins important in the GeneDx lawsuit?

Gross margins help investors assess profitability and operational efficiency over time.

What are investors alleging GeneDx failed to disclose?

The complaint claims the company did not fully reveal risks tied to reimbursement trends and margin performance.

Who may qualify to participate in the GeneDx class action?

What is the deadline to seek lead plaintiff status in the GeneDx lawsuit?

Investors seeking appointment as lead plaintiff must file a motion by August 3, 2026.

What is a securities class action lawsuit?

A securities class action allows investors to collectively pursue claims against a company for misleading statements or omissions.

What does the term “class period” mean in a securities lawsuit?

The class period is the timeframe when alleged misleading statements occurred and investors may have purchased shares.

What is a lead plaintiff in a securities class action?

The lead plaintiff is the investor selected by the court to represent the interests of all shareholders in the litigation.

How do investors receive compensation from a securities class action settlement?

If a settlement is reached, investors submit claim forms documenting eligible transactions to receive a portion of the settlement fund.

GeneDx Holdings Corp. - Faruqi & Faruqi LLP

GeneDx Holdings Corp.

Join Action

Case Details

Ticker WGS

Class Period 04/16/2025 - 05/04/2026

Lead Plaintiff Deadline 08/03/2026

Days Left to Seek Plaintiff

If you are a GeneDx investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company may have misled investors about the importance of Fabric Genomics; (2) as a result, the Company’s margins would suffer; (3) the company’s average reimbursement rates were not as “durable” as previously disclosed; (4) as a result of the foregoing, the Company’s gross margins would decline; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Lead Plaintiff Deadline: August 3, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

GeneDx Holdings Corp.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify